<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Insulin lispro (conventional and faster-acting): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Insulin lispro (conventional and faster-acting): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Insulin lispro (conventional and faster-acting): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9025" href="/d/html/9025.html" rel="external">see "Insulin lispro (conventional and faster-acting): Drug information"</a> and <a class="drug drug_patient" data-topicid="11770" href="/d/html/11770.html" rel="external">see "Insulin lispro (conventional and faster-acting): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2127784"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Admelog;</li>
<li>Admelog SoloStar;</li>
<li>HumaLOG;</li>
<li>HumaLOG Junior KwikPen;</li>
<li>HumaLOG KwikPen;</li>
<li>HumaLOG Tempo Pen;</li>
<li>Lyumjev;</li>
<li>Lyumjev KwikPen;</li>
<li>Lyumjev Tempo Pen</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868725"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Admelog;</li>
<li>Admelog SoloStar;</li>
<li>HumaLOG Junior KwikPen;</li>
<li>HumaLOG KwikPen</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F991022"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidiabetic Agent, Parenteral</span>;</li>
<li>
<span class="list-set-name">Insulin, Rapid-Acting</span></li></ul></div>
<div class="block dop drugH1Div" id="F2127827"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Insulin lispro is a rapid-acting insulin analog available in a conventional formulation (eg, Admelog, Humalog) and an ultra-rapid formulation (Lyumjev), which differ in onset of action, administration instructions, and approved ages for use. Insulin doses should be individualized based on patient needs; adjustments may be necessary with changes in physical activity, meal patterns, acute illness, or with changes in renal or hepatic function. Insulin requirements vary dramatically between patients and dictates frequent monitoring and close medical supervision. Insulin regimens vary widely by region, practice, and institution; consult institution-specific guidelines.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5956846-9e6c-4def-954b-a126316b2bbe">Diabetes mellitus, type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1:</b> Children and Adolescents: <b>Note:</b> Insulin lispro is generally used concomitantly with intermediate- or long-acting insulin (ie, multiple daily injection regimen) or via a continuous SubQ insulin infusion pump (Humalog U-100 and Admelog U-100 only). The daily doses presented are expressed as the <b>total units/kg/day of all insulin formulations combined</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General insulin dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial total daily insulin: </i>SubQ: Initial: 0.4 to 0.5 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020'])">Ref</a></span>) usual range: 0.4 to 1 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-15616254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-15616254'])">Ref</a></span>); lower doses (0.25 units/kg/day) may be used, especially in young children, to avoid potential hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472948'])">Ref</a></span>); higher doses may be necessary for some patients (eg, obese, concomitant steroids, puberty, sedentary lifestyle, following diabetic ketoacidosis presentation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-15616254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-15616254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Usual total daily maintenance range:</i> SubQ: Doses must be individualized; however, an estimate can be determined based on phase of diabetes and level of maturity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29999222','lexi-content-ref-28726299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29999222','lexi-content-ref-28726299'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Partial remission phase (Honeymoon phase): &lt;0.5 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Prepubertal children (not in partial remission):</p>
<p style="text-indent:-2em;margin-left:10em;">Infants ≥6 months and Children ≤6 years: 0.4 to 0.8 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥7 years: 0.7 to 1 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1 unit/kg/day and in some cases up to 2 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Division of daily insulin requirement (multiple daily injections):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Basal insulin: Generally, ~30% to 50% of the total daily insulin is given as basal insulin (intermediate- or long-acting) in 1 to 2 daily injections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-29999222','lexi-content-ref-Peters.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-29999222','lexi-content-ref-Peters.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Prandial insulin: The remaining portion of the total daily dose is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting (eg, aspart, glulisine, lispro) or short-acting (regular). In most type 1 patients, the use of a rapid-acting insulin analog is preferred over regular insulin to reduce hypoglycemia risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-24935775','lexi-content-ref-29999222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-24935775','lexi-content-ref-29999222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dosage titration:</b> Treatment and monitoring regimens must be individualized to maintain premeal and bedtime glucose in target range; titrate dose to achieve glucose control and avoid hypoglycemia. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Surgical patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30039617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30039617'])">Ref</a></span>)</i>: <b>Note: </b>Diabetic patients should be scheduled as the first case of the day.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Minor surgeries:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Morning procedure: Omit rapid-acting insulin (eg, aspart, glulisine, lispro) until after surgery and patient is able to eat unless it is needed to correct significant hyperglycemia and/or significant ketone (&gt;0.1 mmol/mol) production is present.</p>
<p style="text-indent:-2em;margin-left:10em;">Afternoon procedure: If allowed to eat breakfast, administer the usual dose of rapid-acting insulin (eg, aspart, glulisine, lispro) with breakfast.</p>
<p style="text-indent:-2em;margin-left:10em;">Postprocedure: Once normal oral intake is achieved, resume usual insulin regimen; monitor closely; insulin requirement may be higher due to changes related to surgery (ie, postoperative stress, medication changes, inactivity).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Major surgeries:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Evening prior to surgery: Administer the usual evening and/or bedtime insulin(s); patients on continuous subcutaneous insulin infusion (CSII) may continue normal insulin basal rates overnight; if there is a concern for hypoglycemia, basal rate may be reduced by 20% at ~3 am.</p>
<p style="text-indent:-2em;margin-left:10em;">Morning of surgery: Omit morning insulin (short- and long-acting) and start IV insulin (regular) infusion and IV dextrose at least 2 hours prior to surgery; patients on CSII should discontinue CSII when IV insulin infusion is started.</p>
<p style="text-indent:-2em;margin-left:10em;">Postprocedure: Once normal oral intake is achieved, resume usual insulin regimen; monitor closely; insulin requirement may be higher due to changes related to surgery (ie, postoperative stress, medication changes, inactivity).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="570f091a-c1c1-46a6-9d95-172eadddf365">Diabetes mellitus, type 2</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2:</b> Children ≥10 years and Adolescents: SubQ: The goal of therapy is to achieve an HbA<sub>1c</sub> &lt;7% as quickly as possible using the safe titration of medications. Initial therapy in metabolically unstable patients (eg, plasma glucose ≥250 mg/dL, HbA<sub>1c</sub> &gt;8.5%, symptoms excluding acidosis) may include once-daily intermediate-acting insulin or basal insulin in combination with lifestyle changes and metformin. In patients who fail to achieve glycemic goals with metformin and basal insulin, may consider initiating prandial insulin (regular insulin or rapid-acting insulin) and titrate to achieve goals. Once initial goal reached, insulin should be slowly tapered over 2 to 6 weeks by decreasing the insulin dose by 10% to 30% every few days and the patient transitioned to lowest effective doses or metformin monotherapy if able (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23359574','lexi-content-ref-ADA.2020','lexi-content-ref-30425094','lexi-content-ref-29999228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23359574','lexi-content-ref-ADA.2020','lexi-content-ref-30425094','lexi-content-ref-29999228'])">Ref</a></span>). <b>Note:</b> Patients who are ketotic or present with ketoacidosis require aggressive management.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c0530af-c6d3-4cf5-a815-8e4e90cb9338">Diabetic ketoacidosis, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic ketoacidosis (DKA), uncomplicated: </b>Limited data available: Infants, Children, and Adolescents: SubQ: 0.15 units/kg/dose every 2 to 3 hours until resolution of metabolic acidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29900641','lexi-content-ref-20550713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29900641','lexi-content-ref-20550713'])">Ref</a></span>); if serum glucose decreases by &gt;100 mg/dL/hour, reduce dose to 0.1 units/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20550713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20550713'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51114019"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements are reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block dohp drugH1Div" id="F51114020"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block doa drugH1Div" id="F2127828"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9025" href="/d/html/9025.html" rel="external">see "Insulin lispro (conventional and faster-acting): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Insulin lispro is a rapid-acting insulin analog available in a conventional formulation (eg, Admelog, Humalog) and an ultra-rapid formulation (Lyumjev), which differ in onset of action and administration instructions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27987252','lexi-content-ref-32468448','lexi-content-ref-32468447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27987252','lexi-content-ref-32468448','lexi-content-ref-32468447'])">Ref</a></span>). Insulin requirements vary between patients; monitor glucose levels frequently and individualize dose. When switching between insulin lispro products, continue with the same insulin dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc2823b3-202c-4a44-a2d1-58b5084839e6">Diabetes mellitus, type 1, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Insulin lispro must be used concomitantly with intermediate- or long-acting insulin (ie, multiple daily injection regimen) or via a continuous SUBQ insulin infusion device (U-100 only). <b>The total daily doses (TDD) presented below are expressed as the total units/kg/day of all insulin formulations combined.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General insulin dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Initial TDD:</i></b>
<b>SUBQ: </b>~0.4 to 0.5 units/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-29222382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-29222382'])">Ref</a></span>); conservative initial doses of 0.2 to 0.4 units/kg/day may be considered to avoid the potential for hypoglycemia; higher initial doses may be required in patients with obesity, or who are sedentary or presenting with ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-29222382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-29222382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Usual TDD maintenance range:</i></b>
<b>SUBQ: </b>0.4 to 1 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29222382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29222382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Division of TDD (multiple daily injections):</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Basal insulin: Generally, 40% to 50% of the TDD is given as basal insulin (intermediate- or long-acting) in 1 to 2 daily injections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-29222382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-29222382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Prandial insulin: The remaining portion (ie, 50% to 60%) of the TDD is then divided and administered before, at, or just after mealtimes depending on the formulation (eg, short-, rapid-, ultra-rapid-acting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-29222382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-29222382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Dosage adjustment: </b></i>Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used if glycemic targets are not met despite adequately titrated basal insulin (eg, fasting glucose levels not at goal, basal insulin dose &gt;0.5 units/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29222382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29222382'])">Ref</a></span>). For regimens containing basal and prandial insulin, consider discontinuing noninsulin agents other than metformin, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29222382','lexi-content-ref-30291106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29222382','lexi-content-ref-30291106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Initial:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Prandial insulin regimens are typically initiated as one daily injection administered before the largest meal; additional mealtime injections may be added based on results of glucose monitoring. In patients with HbA<sub>1c</sub> &lt;8% when prandial insulin is initiated, consider reducing the basal insulin daily dose by 4 units/day <b>or</b> by 10% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-29222382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-29222382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ: </b>4 to 6 units <b>or</b> 10% of the <b>basal </b>insulin dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-29222382','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-29222382','lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Dosage adjustment: </i>Note: </b>Individualize dosage adjustments based on patient-specific factors (eg, glucose levels, carbohydrate intake) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29222382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29222382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For persistently elevated glucose levels: SUBQ: </b>Consider intensification of dietary modifications and/or increasing the corresponding mealtime dose(s) by 1 to 2 units <b>or</b> by 10% to 15% every 3 days to achieve glycemic targets while avoiding hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29222382','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29222382','lexi-content-ref-Wexler.1'])">Ref</a></span>). <b>Note:</b> More aggressive dose increases (eg, by ≥5 units) may be required in patients already taking &gt;20 units/dose of insulin lispro (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For hypoglycemia: SUBQ: </b>For unexplained mild to moderate hypoglycemia, consider decreasing the corresponding mealtime dose(s) by 10% to 20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29222382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29222382'])">Ref</a></span>); for hypoglycemia requiring assistance from another person or blood glucose &lt;40 mg/dL, consider decreasing the corresponding mealtime dose(s) by 20% to 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-Wexler.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="87b665ef-68eb-453a-80ad-91aa786100ef">Patients with diabetes receiving enteral feedings</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Patients with diabetes receiving enteral feedings: Note:</b> TDD of insulin is divided into a basal component (intermediate- or long-acting insulin) and nutritional and correctional components (regular insulin or rapid-acting insulins).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nutritional:</i>
<b>SUBQ:</b> 1 unit of insulin lispro per 10 to 15 g of carbohydrate prior to each bolus feeding; in patients receiving continuous feeds, administer every 4 hours based on the amount of carbohydrate administered over each 4-hour period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29222382','lexi-content-ref-15336577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29222382','lexi-content-ref-15336577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Correctional:</i>
<b>SUBQ</b>: Administer correctional insulin as needed prior to each feeding (for bolus feeds) or every 4 hours (for continuous feeds) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>). Dosing is individualized; one example of an empiric correctional dose is 1 to 2 units per 40 to 50 mg/dL above target glucose level; patients with known insulin resistance or who are receiving glucocorticoids may require higher correctional doses (eg, 4 units per 50 mg/dL above target glucose level) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747243','lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-Magaji.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747243','lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-Magaji.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="416ede05-90f0-450c-a473-d7b0ea1dad5e">Patients with diabetes undergoing surgery and using an insulin pump</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Patients with diabetes undergoing surgery and using an insulin pump:</b>
<b>SUBQ:</b> For short procedures (eg, &lt;2 hours), continue the usual pump "basal" insulin infusion rate, with or without a temporary 20% to 40% rate reduction, on the morning of the procedure. For long and complex procedures, consider transitioning from the insulin pump to an IV regular insulin infusion perioperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29222382','lexi-content-ref-29162977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29222382','lexi-content-ref-29162977'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="227d5854-46f0-42a3-acb6-6009a78c892a">Diabetic ketoacidosis, mild to moderate, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic ketoacidosis, mild to moderate, uncomplicated (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> SUBQ insulin lispro may be used as an alternative to IV regular insulin in patients in whom management of diabetic ketoacidosis (DKA) outside of a critical care area is appropriate; faster-acting insulin lispro products (eg, Lyumjev) have not been evaluated for this purpose. IV regular insulin (preferred over IV rapid-acting insulin analogs) should be used in patients with severe DKA, evidence of hyperosmolar hyperglycemic state (eg, altered mental status), persistent hypotension, or other critical illness, as well as during pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28183452','lexi-content-ref-19564476','lexi-content-ref-15277410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28183452','lexi-content-ref-19564476','lexi-content-ref-15277410'])">Ref</a></span>). Begin correction of fluid deficits, if present. If serum potassium is &lt;3.3 mEq/L on initial presentation, delay insulin administration until serum potassium reaches ≥3.3 mEq/L. Address other electrolyte abnormalities, as needed, during insulin administration (Kitabchi 2009). In patients with initial serum glucose &lt;250 mg/dL, initiate dextrose-containing IV fluids at the time of insulin initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28924481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28924481'])">Ref</a></span>). An example of a dosing regimen is as follows; refer to institutional protocols:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>1-hour interval dosing:</i>
<b>SUBQ:</b> 0.3 units/kg once, followed by 0.1 units/kg every hour until blood glucose &lt;250 mg/dL, then decrease to 0.05 units/kg every hour until resolution of ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15277410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15277410'])">Ref</a></span>). May increase dose (eg, by double) if serum glucose does not decrease by ~50 to 75 mg/dL in the first hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.1','lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.1','lexi-content-ref-19564476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>2-hour interval dosing:</i>
<b>SUBQ:</b> 0.3 units/kg once, followed by 0.2 units/kg 1 hour later and then every 2 hours thereafter until blood glucose &lt;250 mg/dL, then decrease to 0.1 units/kg every 2 hours until resolution of ketoacidosis. May increase dose (eg, by double) if serum glucose does not decrease by ~50 to 75 mg/dL in the first hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.1','lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.1','lexi-content-ref-19564476'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70b35ef8-5589-4fcf-8fcb-ab71c5c307ec">Hyperglycemia, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperglycemia, hospitalized patients (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients with persistent hyperglycemia (eg, blood glucose ≥140 to 180 mg/dL for &gt;12 to 24 hours) with or without a history of diabetes; use of institution-specific protocols to achieve glycemic targets and minimize hypoglycemia is encouraged (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-23164767'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Correctional insulin:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For use in addition to scheduled basal and nutritional insulin to achieve glycemic targets; prolonged use of correctional insulin without basal insulin is discouraged (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-19454396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ:</b> Refer to institution-specific protocols; one example of an empiric correctional dose is 1 to 2 units per 40 to 50 mg/dL above target glucose level; dose is typically administered with meals (or bolus feeds) or every 4 hours (if NPO or receiving continuous feeds); patients with known insulin resistance or who are receiving glucocorticoids may require higher correctional doses (eg, 4 units per 50 mg/dL above target glucose level) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-14747243','lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-Magaji.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-14747243','lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-Magaji.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nutritional insulin:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial daily dosage:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Patients not receiving nutritional insulin prior to hospitalization:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Patients eating meals:</i>
<b>SUBQ:</b> 0.03 to 0.1 units/kg/<b>meal </b>administered with or just after meals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765'])">Ref</a></span>). <b>Note: </b>Dose is individualized; consider doses at the lower end of this range in older patients and in those with renal impairment; consider doses at the higher end of this range in patients receiving glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22223765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Patients receiving enteral feeds:</i>
<b>SUBQ:</b> 1 unit of insulin lispro per 10 to 15 g of carbohydrate prior to each bolus feeding; in patients receiving continuous feeds, administer every 4 hours based on the amount of carbohydrate administered over each 4-hour period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Patients receiving nutritional insulin prior to hospitalization: <b>SUBQ:</b> Continue the pre-hospitalization nutritional insulin dose; an empiric 25 to 50% dose reduction may be considered in patients with impaired renal function, poor nutritional intake, or admission glucose levels &lt;100 mg/dL; higher doses may be required in patients receiving glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-Inzucchi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-Inzucchi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment:</i> Adjust daily dose by 10% to 20% every 2 to 3 days to achieve glycemic targets. Consider reducing dosage for glucose levels &lt;100 mg/dL to avoid hypoglycemia; in patients with glucose levels &lt;40 mg/dL, larger dose reductions (eg, by 20% to 40%) may be needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-19454396'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990840"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may be needed as insulin requirements may be reduced due to changes in insulin clearance or metabolism.</p></div>
<div class="block doha drugH1Div" id="F50988063"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may be needed as insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block adr drugH1Div" id="F2127803"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics and may include concomitant basal insulin.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Severe hypoglycemia (≤14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (19% to 33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site reaction (3% to 38%; includes infusion-site pain [16%])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache, pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, flu-like symptoms, nasopharyngitis (5% to 15%), pharyngitis, rhinitis</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (3% to 6%, may be secondary to excipient; including bruising at injection site, erythema at injection site, inflammation at injection site, injection-site pruritus, pain at injection site, rash at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (may be secondary to excipient)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, upper respiratory tract infection (1% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Hypertrophy at injection site, lipoatrophy at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Endocrine &amp; metabolic: Hypokalemia, weight gain</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Endocrine &amp; metabolic: Amyloidosis (localized cutaneous)</p></div>
<div class="block coi drugH1Div" id="F2127798"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to insulin lispro or any component of the formulation; during episodes of hypoglycemia.</p></div>
<div class="block war drugH1Div" id="F2127799"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glycemic control: Hyper- or hypoglycemia may result from changes in insulin strength, manufacturer, type, injection site, and/or administration method. The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content or timing of meals), changes in the level of physical activity, increased work or exercise without eating, changes to coadministered medications, or sudden changes in the injection site (to unaffected area). Use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long standing diabetes, diabetic nerve disease, patients taking beta-blockers or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia. Hyperglycemia may occur with repeated injections into areas of lipodystrophy or localized cutaneous amyloidosis; changing the injection site is recommended with close monitoring for hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (serious, life-threatening and anaphylaxis) have occurred. If hypersensitivity reactions occur, discontinue administration and initiate supportive care measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with IV insulin use and supplement potassium when necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Type 2 diabetes, hypoglycemia: Closely monitor insulin dose requirement throughout active weight loss with a goal of eliminating antidiabetic therapy or transitioning to agents without hypoglycemic potential; hypoglycemia after gastric bypass, sleeve gastrectomy, and gastric band may occur (Mechanick 2020). Insulin secretion and sensitivity may be partially or completely restored after these procedures (Korner 2009; Peterli 2012). Rates and timing of type 2 diabetes improvement and resolution vary widely by patient. Insulin dose reduction of ≥75% has been suggested after gastric bypass for patients without severe β-cell failure (fasting c-peptide &lt;0.3 nmol/L) (Cruijsen 2014). Avoid the use of bolus insulin injections or dose conservatively with close clinical monitoring in the early phases after surgery.</p>
<p style="text-indent:-2em;margin-left:6em;">– Weight gain: Insulin therapy is preferred if antidiabetic therapy is required during the perioperative period (Mechanick 2019). Evaluate risk versus benefit of long-term postoperative use and consider alternative therapy due to potential for insulin-induced weight gain (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Concurrent use with peroxisome proliferator-activated receptor (PPAR)-gamma agonists, including thiazolidinediones (TZDs), may cause dose-related fluid retention and lead to or exacerbate heart failure, particularly when used in combination with insulin. If PPAR-gamma agonists are prescribed, monitor for signs and symptoms of heart failure. If heart failure develops, consider PPAR-gamma agonist dosage reduction or therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced, and patients may require more frequent dose adjustment and glucose monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced, and patients may require more frequent dose adjustment and glucose monitoring.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients: Prolonged use of a sliding scale insulin regimen in the inpatient setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion (insulin regular) has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, basal insulin use is preferred, with correctional doses (insulin regular or rapid-acting insulin) as needed. In noncritically ill patients with adequate nutritional intake, a combination of basal insulin along with nutritional and correctional components (insulin regular or rapid-acting insulin) is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia. A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Prefilled pen devices: Do not perform dose conversion when using prefilled pen devices; the dose window shows the number of units to be delivered and no conversion is needed. Do not transfer insulin lispro from a prefilled pen to a syringe.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple-dose injection pens: According to the CDC, pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CSII administration: Insulin lispro U-100 (100 units/mL) may be administered via a CSII device; do not dilute or mix with other insulins. Rule out external pump failure if unexplained hyperglycemia or ketosis occurs; temporary SUBQ insulin administration may be required until the problem is identified and corrected. Insulin lispro U-200 (200 units/mL) is <b>not</b> indicated for use in a CSII device.</p>
<p style="text-indent:-2em;margin-left:4em;">• IV administration: Insulin lispro U-100 (100 units/mL) may be administered IV in selected clinical situations to control hyperglycemia; close monitoring of blood glucose and serum potassium as well as medical supervision is required. Insulin lispro U-200 (200 units/mL) is <b>not</b> indicated for IV administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patient education: Diabetes self-management education is essential to maximize the effectiveness of therapy.</p></div>
<div class="block dosfc drugH1Div" id="F57559564"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Humalog Tempo Pen: The Tempo Pen contains a component that allows for data connectivity when used with a compatible transmitter. Consult the prescribing information for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">Lyumjev Tempo Pen: The Tempo Pen contains a component that allows for data connectivity when used with a compatible transmitter. Consult the prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F2104242"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Admelog: 100 units/mL (3 mL, 10 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumaLOG: 100 units/mL (3 mL, 10 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyumjev: Insulin lispro-aabc 100 unit/mL (10 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 units/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumaLOG: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Admelog SoloStar: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumaLOG Junior KwikPen: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumaLOG KwikPen: 100 units/mL (3 mL); 200 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumaLOG Tempo Pen: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyumjev KwikPen: Insulin lispro-aabc 100 unit/mL (3 mL); Insulin lispro-aabc 200 unit/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyumjev Tempo Pen: Insulin lispro-aabc 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 units/mL (3 mL)</p></div>
<div class="block geq drugH1Div" id="F2127787"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422168"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Admelog Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $15.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (HumaLOG Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $7.97</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Insulin Lispro Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $3.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lyumjev Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $32.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Cartridge</b> (HumaLOG Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $12.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Admelog SoloStar Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $15.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (HumaLOG Junior KwikPen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $12.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (HumaLOG KwikPen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $12.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 units/mL (per mL): $84.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (HumaLOG Tempo Pen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $12.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Insulin Lispro (1 Unit Dial) Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $12.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Lyumjev KwikPen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $42.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 units/mL (per mL): $84.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Lyumjev Tempo Pen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $42.43</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868726"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Admelog: 100 units/mL (10 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Admelog: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Admelog SoloStar: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumaLOG Junior KwikPen: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumaLOG KwikPen: 200 units/mL (3 mL) [contains metacresol]</p></div>
<div class="block admp drugH1Div" id="F52614090"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Do not use if solution is viscous or cloudy; use only if clear and colorless with no visible particles.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: Avoid cold injections. Administer into the subcutaneous fat of the thighs, arms, buttocks, or abdomen. Rotate injection sites within the same region to reduce the risk of lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Humalog: </i>Administer within 15 minutes before or immediately after a meal. Do not dilute or mix other insulins with insulin lispro contained in a cartridge or prefilled pen. Do not mix insulin lispro U-200 (200 units/mL) with any other insulin.</p>
<p style="text-indent:-2em;margin-left:6em;">Vial: Humalog U-100 (100 units/mL) from a vial may be mixed only with insulin NPH (do not mix with other types of insulin); insulin lispro should be drawn into syringe first. Use immediately after mixing.</p>
<p style="text-indent:-2em;margin-left:6em;">Prefilled pens: Humalog prefilled pens are available in concentrations of 100 units/mL and 200 units/mL. Devices are designed to display the actual insulin units administered (no dosage conversion needed) and will administer up to 30 units per injection in 0.5-unit increments (U-100 Junior KwikPen) or up to 60 units per injection in 1-unit increments (U-100 KwikPen, U-100 Tempo Pen, U-200 KwikPen). Do not transfer insulin lispro U-200 to a syringe for administration; markings on the insulin syringe will not measure the dose correctly and can result in overdosage and severe hypoglycemia. For all Humalog prefilled pen devices, prime the needle before each injection with 2 units of insulin (use a new needle for each injection); see manufacturer's labeling for specific procedure. Once primed, set dial to the appropriate dose, insert needle into clean skin, and activate device by holding the button down; continue to hold the button until the dose dial has returned to 0 units. After the insulin is injected, hold the needle in the skin for 5 seconds after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered. Do not rub the area. If dose is &gt;30 units (U-100 Junior KwikPen) or &gt;60 units (U-100 KwikPen, U-100 Tempo Pen, U-200 KwikPen), &gt;1 injection will be required; split dose and administer in multiple injections.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Admelog: </i>Admelog SoloStar prefilled pen will administer up to 80 units per injection in 1-unit increments. Prior to each injection, the needle must be primed with 2 units of insulin (use a new needle for each injection); see manufacturer's labeling for specific procedure. Once primed, set dial to the appropriate dose, insert needle into clean skin, and activate device by holding the button down; continue to hold the button until the dose dial has returned to 0 units. After the insulin is injected, hold the needle in the skin for 10 seconds after the dose dial has returned to 0 units to ensure the full dose has been administered. Do not rub the area. If dose is &gt;80 units, &gt;1 injection will be required; split dose and administer in multiple injections. Do not mix other insulin formulations with insulin lispro contained in a prefilled pen.</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous SUBQ insulin infusion (Insulin pump): Admelog and Humalog only: Insulin lispro U-100 (100 units/mL) may be administered via inulin pumps; do not administer insulin lispro U-200 (200 units/mL) via insulin pumps. Do not use if solution is viscous or cloudy; use only if clear and colorless. Patients should be trained in the proper use of their external insulin pump and in intensive insulin therapy. Infusion sets and infusion set insertion sites should be changed every 3 days; rotate infusion sites. Insulin in reservoir should be changed every 7 days or according to insulin pump user manual (whichever is shorter). Do not dilute or mix other insulin formulations with insulin lispro contained in an external insulin pump.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Insulin lispro U-100 (100 units/mL) may be administered IV in selected clinical situations to control hyperglycemia. Closely monitor blood glucose and serum potassium; appropriate medical supervision is required. Further dilute with NS prior to administration. Do not administer insulin mixtures intravenously.</p>
<p style="text-indent:-2em;margin-left:4em;">To minimize adsorption to IV tubing: At low concentrations and flow rates, insulin lispro has been shown to adsorb to PVC IV bags and tubing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10531849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10531849'])">Ref</a></span>). Therefore, flush the IV tubing with a priming volume of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23164767','lexi-content-ref-22746979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23164767','lexi-content-ref-22746979'])">Ref</a></span>). Also refer to institution-specific protocols where appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">Because of adsorption, the actual amount of insulin being administered via IV infusion could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SUBQ dosing regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19454396'])">Ref</a></span>); however, the transition to SUBQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. Transition to a protocol-driven basal/bolus insulin regimen should begin prior to stopping the IV infusion in order to avoid significant loss of glucose control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23164767','lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23164767','lexi-content-ref-19454396'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F2127831"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Use only if solution is clear and colorless; do not use if solution contains particulate matter or is colored.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ administration: Cold injections should be avoided. SUBQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites within the same region to avoid lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Admelog: </i>Administer within 15 minutes before or immediately after a meal. Do not mix with any other insulin. For Admelog SoloStar pen, prime the needle before each injection with 2 units of insulin. Once injected, hold the needle in the skin for ~10 seconds after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Humalog: </i>Administer within 15 minutes before or immediately after a meal. Do not dilute or mix other insulins with insulin lispro contained in a cartridge or prefilled pen. Do not mix insulin lispro U-200 (200 units/mL) with any other insulin. May mix insulin lispro U-100 (100 units/mL) from a vial only with insulin NPH (do not mix with other types of insulin); insulin lispro should be drawn into syringe first; perform injection immediately. Prefilled pen devices are designed to dial doses in 1-unit increments (U-100 KwikPen, U-100 Tempo Pen, U-200 KwikPen) or in 0.5-unit increments (U-100 Junior KwikPen). Do not perform dose conversion when using Humalog prefilled pen devices; the dose window shows the number of units to be delivered and no conversion is needed. Do not transfer insulin lispro U-200 to a syringe for administration. For Humalog prefilled pen devices, prime the needle before each injection with 2 units of insulin. Once injected, hold the needle in the skin for ~5 seconds after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lyumjev: </i>Administer at the start of a meal or within 20 minutes after starting a meal; routine postprandial use should be avoided due to reduced efficacy vs mealtime administration (Klaff 2020). Do not mix with any other insulin. Prefilled pen devices are designed to dial doses in 1-unit increments (U-100 KwikPen, U-100 Tempo Pen, U-200 KwikPen) or in 0.5-unit increments (U-100 Junior KwikPen). Do not perform dose conversion when using prefilled pen devices; the dose window shows the number of units to be delivered and no conversion is needed. Do not transfer insulin lispro U-200 to a syringe for administration. For Lyumjev prefilled pen devices, prime the needle before each injection with 2 units of insulin. Once injected, hold the needle in the skin for ~5 seconds after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered.</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous SUBQ insulin infusion administration: Insulin lispro U-100 (100 units/mL) may be administered via continuous SUBQ insulin infusion (CSII) device (ie, insulin pump); do not administer insulin lispro U-200 (200 units/mL) via a CSII device. Patients should be trained in the proper use of their CSII device and in intensive insulin therapy. Infusion sets and infusion set insertion sites should be changed according to manufacturer’s user manual; rotate infusion sites. Insulin in reservoir should be changed at least every 7 days (Admelog, Humalog), 9 days (Lyumjev), or according to CSII device user manual (whichever is shorter). Do not dilute or mix other insulins with insulin lispro U-100 that is to be used in a CSII device.</p>
<p style="text-indent:-2em;margin-left:2em;">IV administration: Insulin lispro U-100 (100 units/mL) may be administered IV with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required. <b>Do not administer insulin lispro U-200 (200 units/mL) IV.</b>
<b>Do not administer insulin mixtures IV.</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV infusions: To minimize adsorption to IV tubing: At low concentrations and flow rates, insulin lispro has been shown to adsorb to PVC IV bags and tubing (Ling 1999). Therefore, flush the IV tubing with a priming infusion of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23164767','lexi-content-ref-22746979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23164767','lexi-content-ref-22746979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Also refer to institution-specific protocols where appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">Because of insulin adsorption to IV tubing or infusion bags, the actual amount of insulin being administered via IV infusion could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SUBQ dosing regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19454396'])">Ref</a></span>); however, the transition to SUBQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. Transition to a protocol-driven basal/bolus insulin regimen should begin prior to stopping the IV infusion in order to avoid significant loss of glucose control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19454396','lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19454396','lexi-content-ref-23164767'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F2127814"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store <b>unopened</b> vials, cartridges, and prefilled pens under refrigeration between 2°C and 8°C (36°F and 46°F) until the expiration date or at room temperature &lt;30°C (&lt;86°F) for 28 days; do not freeze or use if has been frozen; protect from direct heat and light. Store <b>in-use</b> vials under refrigeration between 2°C and 8°C (36°F and 46°F) or at room temperature &lt;30°C (&lt;86°F) and use within 28 days. Store <b>in-use</b> cartridges and prefilled pens at room temperature &lt;30°C (&lt;86°F) and use within 28 days; do not freeze or refrigerate.</p>
<p style="text-indent:-2em;margin-left:2em;">For continuous SUBQ insulin infusion: Insulin lispro contained within an external insulin pump reservoir should be replaced at least every 7 days (Admelog, Humalog) or 9 days (Lyumjev), and insulin lispro contained within a 3 mL cartridge should be discarded after 7 days; discard if exposed to temperatures &gt;37°C (&gt;98.6°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Diluted solution for SUBQ administration:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Humalog:</i> After dilution may store at 30°C (86°F) for 14 days or at 5°C (41°F) for 28 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Admelog:</i> After dilution may store at 2°C to 8°C (36°F to 46°F) for up to 24 hours or at room temperature ≤30°C (≤86°F) for up to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Diluted solution for IV infusion:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Humalog:</i> Stable in NS for 48 hours when stored under refrigeration between 2°C and 8°C (36°F to 46°F); may then be used at room temperature for an additional 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Admelog:</i> Stable in NS for 24 hours when stored at 2°C to 8°C (36°F to 46°F) or for up to 4 hours room temperature.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lyumjev:</i> Stable in NS or D5W for up to 4 days when stored under refrigeration between 2°C and 8°C (36°F to 46°F) or for up to 12 hours at room temperature.</p></div>
<div class="block usep drugH1Div" id="F53569719"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Improvement of glycemic control in patients with type 1 diabetes mellitus (Admelog, Humalog: FDA approved in ages ≥3 years and adults; Lyumjev: FDA approved in adults); improvement of glycemic control in patients with type 2 diabetes mellitus (Admelog, Humalog, Lyumjev: FDA approved in adults); has also been used for the treatment of diabetic ketoacidosis (DKA).</p></div>
<div class="block mst drugH1Div" id="F2127781"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">HumaLOG may be confused with HumaLOG Mix 50/50, Humira, HumuLIN N, HumuLIN R, NovoLOG</p>
<p style="text-indent:-2em;margin-left:4em;">Humapen Memoir (used with HumaLOG) may be confused with the Humira Pen</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. <b>
<i>Due to the number of insulin preparations, it is essential to identify/clarify the type and strength of insulin to be used.</i></b></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Insulin (short- or rapid-acting insulin products used for sliding scale) is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to higher risk of hypoglycemia associated with sliding scale insulin without improvements in hyperglycemia, regardless of care setting. Avoid insulin regimens that only use short- or rapid-acting insulins dosed based on current blood glucose levels in the absence of basal or long-acting insulin; recommendation does not apply to regimens containing basal or long-acting insulin (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F2127810"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2127809"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: Consider reducing the liraglutide dose if coadministered with insulin. Prescribing information for the Saxenda brand of liraglutide recommends a dose decrease of 50%. Monitor blood glucose for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely for signs and symptoms of hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, consider insulin dose reductions to avoid hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure, and consider pioglitazone dose reduction or discontinuation if heart failure occurs<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F2127830"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>
<div class="block rep_considerations drugH1Div" id="F53350329"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients with diabetes mellitus who wish to conceive should use adequate contraception until glycemic control is achieved (ADA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Insulin lispro is one of the preferred insulins for use in patients with diabetes mellitus planning to become pregnant (Blumer 2013).</p></div>
<div class="block pri drugH1Div" id="F2127794"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Insulin lispro has not been shown to cross the placenta at standard clinical doses (Boskovic 2003; Holcberg 2004; Jovanovic 1999).</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia (ACOG 201 2018). To prevent adverse outcomes prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2022; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, insulin requirements tend to increase as pregnancy progresses, requiring frequent monitoring and dosage adjustments. Following delivery, insulin requirements decrease rapidly (ACOG 201 2018; ADA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Insulin is the preferred treatment of type 1 and type 2 diabetes mellitus in pregnancy, as well as gestational diabetes mellitus when pharmacologic therapy is needed (ACOG 190 2018; ACOG 201 2018; ADA 2022). Insulin lispro is one of the preferred insulins for use in pregnancy (ACOG 190 2018; ACOG 201 2018; Blumer 2013).</p></div>
<div class="block mopp drugH1Div" id="F53569709"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum glucose, electrolytes, HbA<sub>1c</sub> (every 3 months; if patient is stable and meeting treatment goals, may only need twice-yearly testing; unstable patients on intensive therapy [eg, pregnancy] may need more frequent testing) (ADA 2020), renal function (at diagnosis and at least annually) (ADA [Chiang 2014]), hepatic function.</p></div>
<div class="block rerp drugH1Div" id="F53569256"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Plasma Blood Glucose and HbA<sub>1c</sub> Goals for Diabetes Patients: Note:</b> Postprandial blood glucose should be measured when there is a discrepancy between preprandial blood glucose concentrations and HbA<sub>1c</sub> values and to help assess glycemia for patients who receive basal/bolus or pump regimens. It is usually drawn 1 to 2 hours after starting a meal and is considered to be the "peak."</p>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Blood glucose:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Type 1 diabetes:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Capillary glucose measurement: 70 to 180 mg/dL (SI: 3.9 to 10 mmol/L); tighter fasting target (ie, 70 to 144 mg/dL [SI: 3.9 to 8 mmol/L]) is recommended to attain HbA<sub>1c</sub> goals (ISPAD [de Bock 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Type 2 diabetes: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Fasting plasma glucose: 70 to 110 mg/dL (SI: 3.9 to 6.1 mmol/L) (ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:8em;">Postprandial glucose: 70 to 140 mg/dL (SI: 3.9 to 7.8 mmol/L) (ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">HbA<sub>1c</sub>: &lt;7%; target should be individualized; a more stringent goal (&lt;6.5%) may be reasonable if it can be achieved without significant hypoglycemia; lower targets may also be recommended when using insulin pumps and/or continuous glucose monitoring and during the "honeymoon" phase; less aggressive goals (&lt;7.5% or &lt;8%) may be appropriate in patients who cannot articulate symptoms of hypoglycemia, cannot check glucose frequently, have a history of severe hypoglycemia, have extensive comorbid conditions, or lack access to analog insulins, advanced insulin delivery technology, or continuous glucose monitoring (ADA 2023; ISPAD [de Bock 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">Surgical patients (ISPAD [Kapellen 2022]):</p>
<p style="text-indent:-2em;margin-left:6em;">Intraoperative: 90 to 180 mg/dL (SI: 5 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:6em;">ICU, postsurgery: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L).</p></div>
<div class="block pha drugH1Div" id="F2127816"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>
<p style="text-indent:0em;margin-top:2em;">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Insulin stimulates lipoprotein lipase synthesis and activity; this results in hydrolysis of triglycerides into free fatty acids and storage of free fatty acids in adipocytes, thereby reducing circulating triglyceride levels (Rawla 2018; Sadur 1982; Song 2019). In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>
<p style="text-indent:0em;margin-top:2em;">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae</i>. Insulin lispro differs from human insulin by containing a lysine and proline at positions B28 and B29, respectively, in comparison to the proline and lysine found at B28 and B29 in human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin lispro is a rapid-acting insulin analog.</p></div>
<div class="block phk drugH1Div" id="F2127819"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Onset and duration of hypoglycemic effects depend upon the route of administration, site of injection (onset and duration are progressively slower with SUBQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature. Insulin lispro is available in multiple formulations. Humalog and Admelog are highly similar (Kapitza 2017); Lyumjev formulation contains unique excipients (treprostinil and citrate) that facilitate more rapid SUBQ absorption (Leohr 2020; Linnebjerg 2020).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Onset of action: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Admelog: Similar onset to Humalog (Kapitza 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Humalog: 31 minutes (patients with type 1 diabetes) (Linnebjerg 2020); 45 minutes (patients with type 2 diabetes) (Leohr 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Lyumjev: ~15 to 17 minutes (manufacturer's labeling); 20.1 minutes (patients with type 1 diabetes) (Linnebjerg 2020); 32 minutes (patients with type 2 diabetes) (Leohr 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peak effect:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Admelog: ~2.1 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Humalog: 2.4 to 2.8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Lyumjev: ~2 to 2.9 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Admelog: ~6.9 hours (patients with type 1 diabetes) (Kapitza 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Humalog: ~5.7 to 6.6 hours (patients with type 1 diabetes) (Kapitza 2017; Linnebjerg 2020); ~6.7 hours (patients with type 2 diabetes) (Leohr 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Lyumjev: ~4.6 to 7.3 hours (manufacturer's labeling); ~5 hours (patients with type 1 diabetes) (Linnebjerg 2020); ~6.4 hours (patients with type 2 diabetes) (Leohr 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV: Humalog: 0.72 to 1.55 L/kg (inversely related to dose); Lyumjev: 34 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: Admelog, Humalog: 55% to 77%; Lyumjev: 65%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Admelog, Humalog: 51 to 60 minutes; Lyumjev: 44 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Admelog, Humalog: Median: ~50 minutes (Kapitza 2017; manufacturer's labeling [Admelog]); range: 30 to 90 minutes (manufacturer's labeling [Humalog]).</p>
<p style="text-indent:-2em;margin-left:4em;">Lyumjev: 57 minutes; time to reach 50% of peak plasma concentration was 14 minutes shorter compared to Humalog in patients with type 1 diabetes (14.8 vs 29 minutes, respectively) (Linnebjerg 2020) and 11 minutes shorter compared to Humalog in patients with type 2 diabetes (18.6 vs 29.6 minutes respectively) (Leohr 2020).</p></div>
<div class="block phksp drugH1Div" id="F51193238"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Insulin clearance may be reduced in patients with impaired renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Insulin clearance may be reduced in patients with liver failure.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869462"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lyumjev kwikpen</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Insulina Humalog</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Insulin lispro sanofi | Lyumjev</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Insul lispro</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lyumjev</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lyumjev</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lyumjev</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Recombinant Human Insulin Lispro</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lyumjev</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Insulin lispro sanofi | Liprolog | Lyumjev</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Humalog junior kwikpen | Lyumjev</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Insulin lispro sanofi | Liprolog</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Humalog junior kwikpen | Insulin Lispro Dci | Lyumjev</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Insulin lispro sanofi | Lyumjev | Lyumjev junior</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lyumjev</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Liprolog</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Eglucent | Eglucent kwikpen | Humalog</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Humalog junior kwikpen | Insulina lispro Sanofi</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lyumjev</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Humalog hd kwikpen</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Humalog junior kwikpen | Liprolog basal</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Insulin lispro sanofi | Lyumjev</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lyumjev kwikpen</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Insulin lispro sanofi | Lyumjev</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Insulin lispro sanofi | Lyumjev</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lispro insulin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Insulin lispro sanofi | Liprolog</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Admelog solostar | Humalog | Humalog junior kwikpen | Insulin lispro junior kwikpen</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Humalog junior kwikpen | Lyumjev | Lyumjev junior</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Humalog Junior Kwikpen | Humalog Kwikpen | Humalog U200 Kwikpen | Lyumjev | Lyumjev Junior Kwikpen | Lyumjev Kwikpen | Lyumjev U-200 Kwikpen</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lyumjev</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lispro insulin | Rinlis</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Humalog junior kwikpen | Insulin lispro sanofi</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Lyumjev</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Humalog</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Humalog | Insulin lispro sanofi | Lyumjev</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Admelog.1">
<a name="Admelog.1"></a>Admelog (insulin lispro) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi: 10.1097/AOG.0000000000002960.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29222382">
<a name="29222382"></a>American Diabetes Association (ADA). 11. Older Adults: Standards of Medical Care in Diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S119-S125. doi:10.2337/dc18-S011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/29222382/pubmed" id="29222382" target="_blank">29222382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2023">
<a name="ADA.2023"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023.<i> Diabetes Care.</i> 2023;45(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed February 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2020">
<a name="ADA.2020"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2020. <i>Diabetes Care</i>. 2020;43(suppl 1):S1-S212. https://care.diabetesjournals.org/content/43/Supplement_1. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2021">
<a name="ADA.2021"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2022.<i> Diabetes Care.</i> 2022;45(suppl 1):S1-S255. https://diabetesjournals.org/care/issue/45/Supplement_1. Accessed September 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29608329">
<a name="29608329"></a>Anderson PO. Treating diabetes during breastfeeding.<i> Breastfeed Med</i>. 2018;13(4):237-239. doi:10.1089/bfm.2018.0036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/29608329/pubmed" id="29608329" target="_blank">29608329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in <i>J Clin Endocrinol Metab</i>. 2015;100(5):2135-2136]. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi: 10.1210/jc.2014-3415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30425094">
<a name="30425094"></a>Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2018;41(12):2648-2668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/30425094/pubmed" id="30425094" target="_blank">30425094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472948">
<a name="26472948"></a>Beck JK, Cogen FR. Outpatient management of pediatric type 1 diabetes. <i>J Pediatr Pharmacol Ther</i>. 2015;20(5):344-357. doi: 10.5863/1551-6776-20.5.344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/26472948/pubmed" id="26472948" target="_blank">26472948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/24194617 /pubmed" id="24194617 " target="_blank">24194617 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12716794">
<a name="12716794"></a>Boskovic R, Feig DS, Derewlany L, et al. Transfer of insulin lispro across the human placenta: <i>In vitro</i> perfusion studies. <i>Diabetes Care</i>. 2003; 26(5):1390-1394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/12716794/pubmed" id="12716794" target="_blank">12716794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22111719">
<a name="22111719"></a>Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. <i>N Engl J Med</i>. 2011;365(21):2002-2012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/22111719/pubmed" id="22111719" target="_blank">22111719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28183452">
<a name="28183452"></a>Cardoso L, Vicente N, Rodrigues D, Gomes L, Carrilho F. Controversies in the management of hyperglycaemic emergencies in adults with diabetes. <i>Metabolism</i>. 2017;68:43-54. doi:10.1016/j.metabol.2016.11.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/28183452/pubmed" id="28183452" target="_blank">28183452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href="https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html" target="_blank">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935775">
<a name="24935775"></a>Chiang JL, Kirkman MS, Laffel LM, et al; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. <i>Diabetes Care</i>. 2014;37(7):2034-2054. doi:10.2337/dc14-1140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/24935775/pubmed" id="24935775" target="_blank">24935775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747243">
<a name="14747243"></a>Clement S, Braithwaite SS, Magee MF, et al; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. <i>Diabetes Care</i>. 2004;27(2):553-591. doi:10.2337/diacare.27.2.553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/14747243/pubmed" id="14747243" target="_blank">14747243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23359574">
<a name="23359574"></a>Copeland KC, Silverstein J, Moore KR, et al; American Academy of Pediatrics. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. <i>Pediatrics</i>. 2013;131(2):364-382. doi: 10.1542/peds.2012-3494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/23359574/pubmed" id="23359574" target="_blank">23359574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24829176">
<a name="24829176"></a>Cruijsen M, Koehestani P, Huttjes S, Leenders K, Janssen I, de Boer H. Perioperative glycaemic control in insulin-treated type 2 diabetes patients undergoing gastric bypass surgery. <i>Neth J Med</i>. 2014;72(4):202-209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/24829176/pubmed" id="24829176" target="_blank">24829176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29999222">
<a name="29999222"></a>Danne T, Phillip M, Buckingham BA, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):115-135. doi: 10.1111/pedi.12718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/29999222/pubmed" id="29999222" target="_blank">29999222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537523">
<a name="36537523"></a>de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1270-1276. doi:10.1111/pedi.13455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/36537523/pubmed" id="36537523" target="_blank">36537523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058221">
<a name="30058221"></a>DiMeglio LA, Acerini CL, Codner E, et al. ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):105-114. doi:10.1111/pedi.12737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/30058221/pubmed" id="30058221" target="_blank">30058221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32931166">
<a name="32931166"></a>Gianchandani RY, Iyengar JL, Butler SO, et al. Inpatient diabetes guideline for adult non-critically ill patients. Michigan Medicine, University of Michigan; May 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/32931166/pubmed" id="32931166" target="_blank">32931166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17037974">
<a name="17037974"></a>Goldberg PA, Kedves A, Walter K, et al, "'Waste Not, Want Not': Determining the Optimal Priming Volume for Intravenous Insulin Infusions," <i>Diabetes Technol Ther</i>, 2006, 8(5):598-601.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/17037974/pubmed" id="17037974" target="_blank">17037974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Handelsman.1">
<a name="Handelsman.1"></a>Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. <i>Endocr Pract.</i> 2015;21(suppl 1):1-87. https://journals.aace.com/doi/pdf/10.4158/EP15672.GLSUPPL. Accessed April 23, 2020. doi:10.4158/EP15672.GL.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.1">
<a name="Hirsch.1"></a>Hirsch IB. Evidence-based priming. <i>Diabetes Technol Ther</i>. 2006;8(5):521-522.</div>
</li>
<li>
<div class="reference">
                  Hirsch IB, Emmett M. Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15223182">
<a name="15223182"></a>Holcberg G, Tsadkin-Tamir M, Sapir O, et al. Transfer of insulin lispro across the human placenta. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2004; 115(1):117-118.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/15223182/pubmed" id="15223182" target="_blank">15223182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Humalog.1">
<a name="Humalog.1"></a>Humalog (insulin lispro injection [rDNA origin] solution) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25538310">
<a name="25538310"></a>Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i>. 2015;38(1):140-149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/25538310/pubmed" id="25538310" target="_blank">25538310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Inzucchi.1">
<a name="Inzucchi.1"></a>Inzucchi SE. Diabetes facts and guidelines. <a href="https://medicine.yale.edu/intmed/drc/diabetescenter/living/50135_Yale%20National%20F_102165_284_13584_v1.pdf" target="_blank">https://medicine.yale.edu/intmed/drc/diabetescenter/living/50135_Yale%20National%20F_102165_284_13584_v1.pdf</a>. Published 2011. Accessed January 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23164767">
<a name="23164767"></a>Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. <i>Crit Care Med</i>. 2012;40(12):3251-3276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/23164767/pubmed" id="23164767" target="_blank">23164767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30039617">
<a name="30039617"></a>Jefferies C, Rhodes E, Rachmiel M, et al. ISPAD clinical practice consensus guidelines 2018: management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):227-236. doi:10.1111/pedi.12733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/30039617/pubmed" id="30039617" target="_blank">30039617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10480503">
<a name="10480503"></a>Jovanovic L, Ilic S, Pettitt DJ, et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. <i>Diabetes Care</i>. 1999;22(9):1422-1427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/10480503/pubmed" id="10480503" target="_blank">10480503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537521">
<a name="36537521"></a>Kapellen T, Agwu JC, Martin L, et al. ISPAD clinical practice consensus guidelines 2022: management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes</i>. 2022;23(8):1468-1477. doi:10.1111/pedi.13446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/36537521/pubmed" id="36537521" target="_blank">36537521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27987252">
<a name="27987252"></a>Kapitza C, Nowotny I, Lehmann A, et al. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes. <i>Diabetes Obes Metab</i>. 2017;19(5):622-627. doi:10.1111/dom.12856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/27987252/pubmed" id="27987252" target="_blank">27987252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) diabetes work group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23106132">
<a name="23106132"></a>Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in older adults: A consensus report. <i>J Am Geriatr Soc</i>. 2012; doi: 10.1111/jgs.12035.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/23106132/pubmed" id="23106132" target="_blank">23106132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19564476">
<a name="19564476"></a>Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. <i>Diabetes Care</i>. 2009;32(7):1335-1343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/19564476/pubmed" id="19564476" target="_blank">19564476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32488923">
<a name="32488923"></a>Klaff L, Cao D, Dellva MA, et al. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study. <i>Diabetes Obes Metab</i>. Published online June 2, 2020. doi:10.1111/dom.14100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/32488923/pubmed" id="32488923" target="_blank">32488923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi:10.1038/ijo.2009.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32468448">
<a name="32468448"></a>Leohr J, Dellva MA, Coutant DE, et al. Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in patients with type 2 diabetes mellitus: a phase I randomised, crossover study. <i>Clin Pharmacokinet</i>. Published online May 29, 2020. doi:10.1007/s40262-020-00901-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/32468448/pubmed" id="32468448" target="_blank">32468448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29162977">
<a name="29162977"></a>Leung V, Ragbir-Toolsie K. Perioperative management of patients with diabetes [published online November 15, 2017]. <i>Health Serv Insights</i>. doi:10.1177/1178632917735075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/29162977/pubmed" id="29162977" target="_blank">29162977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10531849">
<a name="10531849"></a>Ling J, Hu M, Hagerup T, et al. Lispro insulin: adsorption and stability in selected intravenous devices. <i>Diabetes Educ</i>. 1999;25(2):237-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/10531849/pubmed" id="10531849" target="_blank">10531849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32468447">
<a name="32468447"></a>Linnebjerg H, Zhang Q, LaBell E, et al. Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in younger adults and elderly patients with type 1 diabetes mellitus: a randomised controlled trial. <i>Clin Pharmacokinet</i>. Published online May 29, 2020. doi:10.1007/s40262-020-00903-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/32468447/pubmed" id="32468447" target="_blank">32468447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lyumjev.1">
<a name="Lyumjev.1"></a>Lyumjev (insulin lispro-aabc injection) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Magaji.1">
<a name="Magaji.1"></a>Magaji V, Johnston JM. Inpatient management of hyperglycemia and diabetes. <i>Clinical Diabetes.</i> 2011;29(1):3-9. doi:10.2337/diaclin.29.1.3</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19454396">
<a name="19454396"></a>Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. <i> Endocr Pract</i>. 2009;15(4):353-369.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/19454396/pubmed" id="19454396" target="_blank">19454396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi:10.1007/s11695-012-0622-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Peters.1">
<a name="Peters.1"></a>Peters AP, Laffel L, eds. <i>Type 1 Diabetes Sourcebook</i>. American Diabetes Association; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29923163">
<a name="29923163"></a>Rawla P, Sunkara T, Thandra KC, Gaduputi V. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. <i>Clin J Gastroenterol</i>. 2018;11(6):441-448. doi:10.1007/s12328-018-0881-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/29923163/pubmed" id="29923163" target="_blank">29923163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28924481">
<a name="28924481"></a>Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. <i>Endocrinol Diabetes Metab Case Rep</i>. 2017;2017:17-0081. doi:10.1530/EDM-17-0081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/28924481/pubmed" id="28924481" target="_blank">28924481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15461903">
<a name="15461903"></a>Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/15461903/pubmed" id="15461903" target="_blank">15461903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7040473">
<a name="7040473"></a>Sadur CN, Eckel RH. Insulin stimulation of adipose tissue lipoprotein lipase. Use of the euglycemic clamp technique. <i>J Clin Invest</i>. 1982;69(5):1119-1125. doi:10.1172/jci110547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/7040473/pubmed" id="7040473" target="_blank">7040473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20550713">
<a name="20550713"></a>Savoldelli RD, Farhat SC, Manna TD. Alternative management of diabetic ketoacidosis in a Brazilian pediatric emergency department. <i>Diabetol Metab Syndr</i>. 2010;2:41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/20550713/pubmed" id="20550713" target="_blank">20550713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36161685">
<a name="36161685"></a>Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. <i>Pediatr Diabetes</i>. 2022;23(7):872-902. doi:10.1111/pedi.13409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/36161685/pubmed" id="36161685" target="_blank">36161685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15616254">
<a name="15616254"></a>Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. <i>Diabetes Care</i>. 2005;28(1):186-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/15616254/pubmed" id="15616254" target="_blank">15616254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31215460">
<a name="31215460"></a>Song X, Shi D, Cui Q, et al. Intensive insulin therapy versus plasmapheresis in the management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): study protocol for a randomized controlled trial. <i>Trials</i>. 2019;20(1):365. doi:10.1186/s13063-019-3498-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/31215460/pubmed" id="31215460" target="_blank">31215460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28726299">
<a name="28726299"></a>Sundberg F, Barnard K, Cato A, et al. ISPAD Guidelines. Managing diabetes in preschool children. <i>Pediatr Diabetes</i>. 2017;18(7):499-517. doi: 10.1111/pedi.12554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/28726299/pubmed" id="28726299" target="_blank">28726299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22746979">
<a name="22746979"></a>Thompson CD, Vital-Carona J, Faustino EV. The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. <i>Diabetes Technol Ther</i>. 2012;14(10):912-916.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/22746979/pubmed" id="22746979" target="_blank">22746979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15277410">
<a name="15277410"></a>Umpierrez GE, Cuervo R, Karabell A, et al. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. <i>Diabetes Care</i>. 2004; 27(8):1873-1878.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/15277410/pubmed" id="15277410" target="_blank">15277410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22223765">
<a name="22223765"></a>Umpierrez GE, Hellman R, Korytkowski MT, et al; Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(1):16-38. doi:10.1210/jc.2011-2098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/22223765/pubmed" id="22223765" target="_blank">22223765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15336577">
<a name="15336577"></a>Umpierrez GE, Latif K, Stoever J, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. <i>Am J Med</i>. 2004;117(5):291-296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/15336577/pubmed" id="15336577" target="_blank">15336577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.2">
<a name="Wexler.2"></a>Wexler DJ. COVID-19: issues related to diabetes mellitus in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Insulin therapy in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22500167">
<a name="22500167"></a>Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/22500167/pubmed" id="22500167" target="_blank">22500167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29900641">
<a name="29900641"></a>Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. <i>Pediatr Diabetes</i>. 2018;19(Suppl 27):155–177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/29900641/pubmed" id="29900641" target="_blank">29900641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29999228">
<a name="29999228"></a>Zeitler P, Arslanian S, Fu J, Pinhas-Hamiel O, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):28-46. doi: 10.1111/pedi.12719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-lispro-conventional-and-faster-acting-pediatric-drug-information/abstract-text/29999228/pubmed" id="29999228" target="_blank">29999228</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12772 Version 321.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
